https://www.instituteatprecision.com https://www.instituteatprecision.com/insights https://www.instituteatprecision.com/experts https://www.instituteatprecision.com/about https://www.instituteatprecision.com/contact https://www.instituteatprecision.com/events https://www.instituteatprecision.com/post/advancing-radiopharmaceuticals-from-regulatory-approval-to-global-access https://www.instituteatprecision.com/post/ai-powered-real-world-evidence-generation-for-biotechs https://www.instituteatprecision.com/post/are-rare-brain-diseases-the-next-commercial-frontier-for-gene-therapy https://www.instituteatprecision.com/post/aspyre-lung-addresses-critical-gaps-in-ngs-based-biomarker-testing https://www.instituteatprecision.com/post/bluebird-bio-innovation-and-challenges-in-cell-gene-therapy https://www.instituteatprecision.com/post/breaking-through-in-hematologic-malignancies https://www.instituteatprecision.com/post/can-distributional-cost-effectiveness-analysis-dcea-actually-inform-on-and-improve-health-equity-in-oncology-perspectives-from-the-methodologist-physician-and-payer https://www.instituteatprecision.com/post/caregiving-in-alzheimers-and-related-dementias-finding-opportunities-to-optimize-caregiver-support https://www.instituteatprecision.com/post/cgt-is-in-its-infancy-for-cns-disorders-but-technical-strides-being-made https://www.instituteatprecision.com/post/challenges-and-opportunities-for-radiopharmaceutical-commercialization https://www.instituteatprecision.com/post/characterized-biospecimens-a-guide-for-leveraging-deeply-characterized-biospecimens-to-support-successful-therapeutic-diagnostic-development https://www.instituteatprecision.com/post/clinical-outcomes-of-pd-1-pd-l1-inhibitors-among-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-with-braf-erbb2-her2-met-or-ret-alterations https://www.instituteatprecision.com/post/cohort-management-best-practices-for-early-phase-oncology-clinical-trials https://www.instituteatprecision.com/post/designing-seamless-phase-1-2-oncology-trials https://www.instituteatprecision.com/post/detection-of-regulatory-t-cells-a-comparison https://www.instituteatprecision.com/post/evolutions-in-oncology-cell-therapy https://www.instituteatprecision.com/post/exploring-decision-makers-challenges-and-strategies-when-selecting-multiple-systematic-reviews https://www.instituteatprecision.com/post/exploring-the-intricacies-of-the-immune-system-a-practical-guide https://www.instituteatprecision.com/post/fda-accelerated-approval-implications-for-treatment-innovation-in-oncology https://www.instituteatprecision.com/post/flexible-car-t-monitoring-period-could-help-with-post-treatment-barriers https://www.instituteatprecision.com/post/guide-to-successfully-conducting-tissue-cross-reactivity-studies https://www.instituteatprecision.com/post/guide-to-using-liquid-biopsy-analysis-in-therapeutic-development https://www.instituteatprecision.com/post/heor-value-demonstration-for-antibody-drug-conjugates-lessons-learned-from-the-first-25-years https://www.instituteatprecision.com/post/how-health-systems-are-using-ai-in-clinical-decision-making https://www.instituteatprecision.com/post/how-to-align-pricing-contracting-with-stakeholder-needs https://www.instituteatprecision.com/post/immune-cell-profiling-in-translational-research https://www.instituteatprecision.com/post/improving-patient-access-to-cell-therapy-through-decentralized-manufacturing https://www.instituteatprecision.com/post/innovation-personalization-the-future-of-oncology-how-ai-is-transforming-cancer-care https://www.instituteatprecision.com/post/journey-of-a-therapeutic-antibody-from-preclinical-to-clinical-proof-of-concept-development https://www.instituteatprecision.com/post/managing-operational-complexity-in-early-phase-oncology-radiopharmaceutical-trials https://www.instituteatprecision.com/post/market-outlook-q4-2025-antibody-drug-conjugates-adcs https://www.instituteatprecision.com/post/methods-for-incorporating-non-randomized-evidence-from-single-arm-trials-into-network-meta-analysis-nma https://www.instituteatprecision.com/post/moving-adcs-to-the-frontline-perspectives-from-fda-oncology-experts https://www.instituteatprecision.com/post/navigating-340b-and-rebates-challenges-solutions-and-the-path-forward https://www.instituteatprecision.com/post/navigating-global-regulations-for-radiopharmaceutical-development https://www.instituteatprecision.com/post/optimizing-successful-gene-therapy-development https://www.instituteatprecision.com/post/payer-challenges-for-patient-access-to-autologous-cell-and-gene-therapies https://www.instituteatprecision.com/post/payors-pharma-engage-alternative-payment-models-amid-high-gene-therapy-cost-efficacy-unknowns https://www.instituteatprecision.com/post/pd-l1-expression-on-immune-cells-from-solid-tumor-patients-implications-for-tumor-immunity-and-immunotherapy https://www.instituteatprecision.com/post/pembrolizumab-plus-chemotherapy-for-first-line-treatment-of-advanced-triple-negative-breast-cancer https://www.instituteatprecision.com/post/phase-3-prostate-cancer-case-study-radiopharm-imaging-at-scale https://www.instituteatprecision.com/post/pros-and-cons-of-various-reimbursement-models-for-cell-and-gene-therapies https://www.instituteatprecision.com/post/quantitative-multiplex-immunofluorescence-a-powerful-tool-for-oncology-therapeutic-development https://www.instituteatprecision.com/post/rebuilding-the-ehr-for-primary-care https://www.instituteatprecision.com/post/reimagining-prior-authorization-a-blueprint-for-cms-0057-f-compliance-and-beyond https://www.instituteatprecision.com/post/securing-maintaining-access-reimbursement-for-rare-disease-therapies https://www.instituteatprecision.com/post/shifting-oncology-management-strategies-among-payers-and-providers https://www.instituteatprecision.com/post/squaring-the-circle-bridging-the-real-world-evidence-gap---before-launch https://www.instituteatprecision.com/post/the-adc-pendulum-following-the-arc-from-approval-to-withdrawal-and-renewed-promise https://www.instituteatprecision.com/post/the-agena-iplex-hs-lung-panel-on-the-massarray-system https://www.instituteatprecision.com/post/the-inside-track-on-market-access-5-trends-shaping-prescribing-in-2025 https://www.instituteatprecision.com/post/the-role-of-pharmaceutical-innovation-in-clinical-practice-guidelines-for-chronic-diseases https://www.instituteatprecision.com/post/twenty-five-years-of-antibody-drug-conjugates-from-breakthroughs-to-access-by-design https://www.instituteatprecision.com/post/understanding-immunogenicity-and-aav-gene-therapy https://www.instituteatprecision.com/post/utilization-of-multiparameter-flow-cytometry-for-immune-monitoring-of-tumor-infiltrating-lymphocytes-isolated-from-fresh-tumor-tissue https://www.instituteatprecision.com/post/validation-of-a-neutralizing-antibody-nab-assay https://www.instituteatprecision.com/post/validation-of-an-approach-to-measure-high-levels-of-neutralizing-antibodies-against-aav-in-human-serum-samples https://www.instituteatprecision.com/post/validation-of-an-ifn-y-elispot-assay-for-measuring-t-cell-responses-against-viral-antigens-in-aav-based-gene-therapy https://www.instituteatprecision.com/post/wall-street-perspective-on-radiopharmaceuticals https://www.instituteatprecision.com/post/why-antibody-drug-congugates-are-revolutionizing-precision-oncology https://www.instituteatprecision.com/post/why-cardiovascular-kidney-metabolic-health-is-a-priority-for-payers-what-it-means-for-manufacturers